This Guidance for Addressing FDA Inspections of Food Ingredient and Dietary Supplement Facilities has been prepared to assist AHPA members in understanding their rights and obligations when the U.S. Food and Drug Administration (FDA) conducts an inspection of a facility in which food ingredients or dietary supplements are manufactured, processed, packed or held. It provides descriptions and analyses of the current federal laws that are relevant to inspection of food ingredient and dietary supplement facilities and suggestions of how to prepare for and conduct inspections in a manner that fully complies with these laws.
FDA’s inspection authority and procedures are different for each of the various classes of consumer goods over which that agency holds jurisdiction. FDA inspects most food ingredient facilities, whether the ingredients are intended for inclusion in conventional foods or in dietary supplements, in accordance with the regulation for current good manufacturing practice (cGMP) for manufacturing, packing and holding human food, as codified at Title 21 of the Code of Federal Regulations, Part 110 (21 CFR 110). Finished product dietary supplement companies are inspected to comply with the cGMP regulations for manufacturing, packing, labeling or holding dietary supplements, which are found at 21 CFR 111.
This Guidance is therefore based on FDA’s cGMP rules for inspecting foods with respect to ingredient manufacturers, and is based on FDA’s cGMPs for dietary supplements for companies that manufacture, pack, label, or hold dietary supplements. There are, however, additional requirements that apply to certain food and dietary supplement classes (e.g., infant formulas; acidified foods; low-acid canned foods; and fish and fishery products3), as well as to drugs and medical devices. Companies that also manufacture, process, pack or hold products such as acidified supplements and fish-oil supplements, or homeopathic and other nonprescription drugs, may therefore need to understand regulations that are not addressed herein.
This Guidance is provided in four sections, presented in a question and answer format, and two appendices. These are:
- Part 1 is an overview of FDA’s inspection authority, which derives from the Federal Food, Drug and Cosmetic Act, the Public Health Security and Bioterrorism Preparedness and Response Act, the Dietary Supplement and Nonprescription Drug Consumer Protection Act, the Reportable Food Registry requirements of the Food and Drug Administration Amendments Act, and the food and dietary supplement cGMPs (i.e., 21 CFR 110 and 111).
- Part 2 is the shortest but perhaps most essential section of this Guidance, as it provides suggestions on the steps that a firm should take in advance to be prepared for an FDA inspection.
- Part 3 provides guidance on what should be expected during an inspection by FDA personnel.
- Part 4 discusses the observational findings that follow an inspection and the need to maintain a thorough internal record of each inspection.
- Appendix 1 is a template for establishing a written standard operating procedure for FDA inspections. This template incorporates much of the information contained in the main section of this Guidance.
- Appendix 2 provides the relevant text of the laws and regulations upon which FDA’s inspection authority is based.
In addition, any company using this Guidance should be aware of the cGMP regulations that apply to its specific operations, as these form the primary basis upon which most inspections are conducted. It is a good practice to print copies of these and maintain them in files that are readily accessible during an FDA inspection. As already noted, for food ingredient facilities the relevant rule is 21 CFR 110 and for dietary supplement facilities it is 21 CFR 111 (though see footnote on prior page for other parts of the rules that apply in some facilities).
Because federal laws and regulations can be amended from time to time, it is important to be aware of any such amendments and to understand the current status of all relevant rules. Users of this Guidance must also pay attention to the disclaimer on the cover page of this document.
Member price: $220
Non-member price: $520
Webinar Recording Details
Presented: March 22, 2016
Duration: Two hours
Cost: $220 - AHPA Members
- Video Recording (MP4)
- Presenter Slides
- AHPA Microbial Level Chart
- Speaker Bios
The Botanical Safety Handbook, Second Edition includes:
- Easily understood classification systems to indicate the safety of each listed species and the potential for drug interactions
- Information on adverse events reported in clinical trials or case reports
- Safety-related pharmacology and pharmacokinetics of each herb
- Additional information on the use of herbs by pregnant or lactating women
- Toxicological studies and data on toxic compounds
- Extensive references for each entry
The book is available in hardback print and online formats. Both versions contain the same information, but the online version, which is optimized for smartphones and tablets, has several additional attributes. Some of these relate to its operation, as it allows subscribers to search for keywords and botanical names and easily access the information they use most by saving personalized lists of entries. Perhaps more importantly, the online version will be updated regularly with new research, and subscribers will be notified of updates to provide immediate access to the most current information. The standard retail cost for either version is $119.95 (one-time cost in print; a renewable annual subscription online). We are discounting the cost for our members and would be happy to offer a discount to other organizations. A free preview of several entries are available online:
Subscribe to the online version or purchase a hardcover copy today. AHPA's Botanical Safety Handbook, Second Edition Print Version: 1,042 pages, revised edition published in 2013 AHPA's Botanical Safety Handbook, Second Edition Online
Member annual subscription: $95.00
Non-member annual subscription: $119.00 Discounts available for multiple user subscriptions.